The hallmark of ITP is the presence of autoantibodies against platelet surface glycoproteins such as GPIIb/IIIa and GPIb/IX.[17] Complement activation via the classical pathway may contribute to platelet destruction in some patients. This evidence concerns the gene ITGA2B and autoimmune thrombocytopenic purpura.